A1166C Angiotensin II Type 1 Receptor Gene Polymorphism May Predict Hemodynamic Response to Losartan in Patients with Cirrhosis and Portal Hypertension

Sookoian, Silvia; Castaño, Gustavo; García, Silvia I.; Viudez, Pedro; González, Claudio; Pirola, Carlos J.
March 2005
American Journal of Gastroenterology;Mar2005, Vol. 100 Issue 3, p636
Academic Journal
OBJECTIVE: Losartan, a dose of 25 mg/day, has been found to be effective in 50% of patients with portal hypertension without adverse effects. We evaluated the relationship between genetic polymorphisms of the renin-angiotensin system (A1166C angiotensin II type 1 receptor (AT1R), angiotensinogen T174M and M235T, and angiotensin-converting enzyme I/D) and the effects of losartan on portal and systemic hemodynamic in patients with cirrhosis and portal hypertension.METHODS: We performed a longitudinal study that included 23 consecutive patients with cirrhosis and esophageal varices who received 25 mg/day of losartan during 12 wk. Hepatic venous pressure gradient (HVPG) and systemic hemodynamic were measured at baseline and after treatment. Genomic DNA was extracted from peripheral blood leukocytes; genetic polymorphisms of the renin-angiotensin system were investigated by polymerase chain reaction and restriction fragment length polymorphisms.RESULTS: The homozygous patients for AT1R A allele showed higher pulmonary-wedged and free hepatic venous pressure on baseline. After treatment, they showed a higher decrease of HVPG (32.5%± 19.2) in comparison with patients with AC/CC genotype (2.4%±18.9),p<0.01. Ten of 15 patients with AA genotype were responders, while only one of eight with AC/CC genotype (p<0.002); genotype AA showed a positive predictive value of 66.6% and negative predictive value of 87.5%.CONCLUSIONS: These results suggest that there is a relationship between the AT1R A1166C polymorphisms and the therapeutic response to losartan. The genetic testing may be used as a predictive factor of this response.(Am J Gastroenterol 2005;100:636–642)


Related Articles

  • Chronic Administration of Losartan, an Angiotensin II Receptor Antagonist, is not Effective in Reducing Portal Pressure in Patients with Preascitic Cirrhosis. Tripathi, Dhiraj; Therapondos, George; Lui, Hock F.; Johnston, Neil; Webb, David J.; Hayes, Peter C. // American Journal of Gastroenterology;Feb2004, Vol. 99 Issue 2, p390 

    OBJECTIVES: Plasma angiotensin II (ANG II) concentrations are elevated in cirrhosis and have been implicated as a cause of portal hypertension. We aimed to study both the systemic and portal hemodynamics, and tolerability after chronic administration of losartan, an ANG II receptor...

  • Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver Cirrhosis. Klein, Sabine; Herath, Chandana B.; Schierwagen, Robert; Grace, Josephine; Haltenhof, Tom; Uschner, Frank E.; Strassburg, Christian P.; Sauerbruch, Tilman; Walther, Thomas; Angus, Peter W.; Trebicka, Jonel // PLoS ONE;9/25/2015, Vol. 10 Issue 9, p1 

    Background & Aims: Although in cirrhosis with portal hypertension levels of the vasoconstrictor angiotensin II are increased, this is accompanied by increased production of angiotensin (Ang)-(1–7), the endogenous ligand of the Mas receptor (MasR), which blunts hepatic fibrosis and...

  • Portal hemodynamics as predictors of high risk esophageal varices in cirrhotic patients. Tarzamni, Mohammad K.; Somi, Mohammad H.; Farhang, Sara; Jalilvand, Morteza; Yoshida, Hiroshi; Rosa, Heitor // World Journal of Gastroenterology;3/28/2008, Vol. 14 Issue 12, p1896 

    AIM: To evaluate portal hypertension parameters in liver cirrhosis patients with and without esophageal varices (EV). METHODS: A cohort of patients with biopsy confirmed liver cirrhosis was investigated endoscopically and with color Doppler ultrasonography as a possible noninvasive predictive...

  • Portopulmonary hypertension: distinctive hemodynamic and clinical manifestations. Yang, Ying-Ying; Lin, Han-Chieh; Lee, Wui-Chiang; Hou, Ming-Chih; Lee, Fa-Yauh; Chang, Full-Young; Lee, Shou-Dong // Journal of Gastroenterology;2001, Vol. 36 Issue 3, p181 

    Abstract: Portopulmonary hypertension is now recognized as one of the pulmonary complications of chronic liver disease. However, previous studies reported that the incidence ranged from 0.25% to 2%, excluding fortuitous coincidence. In this study, we aimed to determine the variant hemodynamic...

  • Evaluation of Rectal Mucosal Hemodynamics in Patients with Liver Cirrhosis Using Reflectance Spectrophotometry. Tezuha, Takashi; Akita, Yasushi; Yoshikawa, Nozomi; Mitamura, Keiji // American Journal of Gastroenterology;Jun1997, Vol. 92 Issue 6, p1022 

    Objectives: Portal hypertensive colonopathy is observed in patients with liver cirrhosis. To determine the correlation between rectal mucosal hemodynamics and portal hypertensive colonopathy, we observed rectal mucosal findings and measured rectal mucosal hemodynamics in patients with liver...

  • Regulation of Hepatic Thrombopoietin Production by Portal Hemodynamics in Liver Cirrhosis. Sezai, Shuichi; Kamisaka, Kazuaki; Ikegami, Fumiaki; Usuki, Kensuke; Urabe, Akio; Tahara, Tomoyuki; Kato, Takashi; Miyazaki, Hiroshi // American Journal of Gastroenterology;Jan1998, Vol. 93 Issue 1, p80 

    Objective: This study was designed to clarify how thrombopoietin (TPO) functions in and, to some extent, causes thrombocytopenia complicating liver cirrhosis and portal hypertension. Methods: Our study population consisted of 19 cirrhotic and six noncirrhotic patients who underwent percutaneous...

  • Hemodynamic Studies in Acute-on-Chronic Liver Failure. Ashish Kumar; Kunal Das; Praveen Sharma; Vimal Mehta; Barjesh Sharma // Digestive Diseases & Sciences;Apr2009, Vol. 54 Issue 4, p869 

    Abstract   Background Patients with decompensated cirrhosis and acute liver failure have circulatory dysfunctions leading to high portal pressure and cardiac output (CO) and low systemic vascular resistance (SVR). Circulatory changes in acute-on-chronic liver failure (ACLF) patients have...

  • Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study. Reverter, Enric; Mesonero, Francisco; Seijo, Susana; Martínez, Javier; Abraldes, Juan G; Peñas, Beatriz; Berzigotti, Annalisa; Deulofeu, Ramon; Bosch, Jaume; Albillos, Agustín; Carles García-Pagán, Joan // American Journal of Gastroenterology;Jul2015, Vol. 110 Issue 7, p985 

    OBJECTIVES:Tetrahydrobiopterin (BH4), a cofactor of nitric oxide synthase, might have a role in the treatment of portal hypertension (PHT) as its administration improves endothelial nitric oxide generation and hepatic endothelial dysfunction, and reduces portal pressure in experimental models of...

  • GSTP1, GSTM1, and GSTT1 genetic polymorphisms in patients with cryptogenic liver cirrhosis Ghobadloo, Shahrokh Mohammadzadeh; Yaghmaei, Bahram; Bakayev, Valery; Goudarzi, Hossein; Noorinayer, Babak; Rad, Farhad Haghighi; Samiy, Saeed; Aghabozorghi, Sohrab; Zali, Mohammad Reza // Journal of Gastrointestinal Surgery;May2004, Vol. 8 Issue 4, p423 

    We investigated glutathione S–transferase (GST) P1 Ile (105) Val, T1, and M1 polymorphisms in 45 patients with documented cryptogenic cirrhosis and 56 healthy control subjects. Polymerase chain reaction–based procedures were performed in the studied populations to confirm the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics